These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9692699)

  • 21. Esomeprazole: a review of its use in the management of acid-related disorders in the US.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(7):1091-118. PubMed ID: 11985491
    [TBL] [Abstract][Full Text] [Related]  

  • 22. On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis--a placebo-controlled randomized trial.
    Lind T; Havelund T; Lundell L; Glise H; Lauritsen K; Pedersen SA; Anker-Hansen O; Stubberöd A; Eriksson G; Carlsson R; Junghard O
    Aliment Pharmacol Ther; 1999 Jul; 13(7):907-14. PubMed ID: 10383525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis.
    Eriksson S; Långström G; Rikner L; Carlsson R; Naesdal J
    Eur J Gastroenterol Hepatol; 1995 May; 7(5):467-75. PubMed ID: 7614110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations.
    Bate CM; Keeling PW; O'Morain C; Wilkinson SP; Foster DN; Mountford RA; Temperley JM; Harvey RF; Thompson DG; Davis M
    Gut; 1990 Sep; 31(9):968-72. PubMed ID: 2210463
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of omeprazole in lower grades of gastro-oesophageal reflux disease.
    Havelund T; Laursen LS; Lauritsen K
    Scand J Gastroenterol Suppl; 1994; 201():69-73. PubMed ID: 8047827
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Omeprazole or high-dose ranitidine in the treatment of patients with reflux oesophagitis not responding to 'standard doses' of H2-receptor antagonists.
    Lundell L; Backman L; Ekström P; Enander LH; Fausa O; Lind T; Lönroth H; Sandmark S; Sandzén B; Unge P
    Aliment Pharmacol Ther; 1990 Apr; 4(2):145-55. PubMed ID: 1983321
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Gastroesophageal reflux disease in intellectually disabled individuals: leads for diagnosis and the effect of omeprazole therapy.
    Bohmer CJ; Niezen-de Boer MC; Klinkenberg-Knol EC; Tuynman HA; Voskuil JH; Devillé WL; Meuwissen SG
    Am J Gastroenterol; 1997 Sep; 92(9):1475-9. PubMed ID: 9317066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Double-blind comparison [correction of Double-blind, placebo-controlled comparison] of rabeprazole 20 mg vs. omeprazole 20 mg in the treatment of erosive or ulcerative gastro-oesophageal reflux disease. The European Rabeprazole Study Group.
    Dekkers CP; Beker JA; Thjodleifsson B; Gabryelewicz A; Bell NE; Humphries TJ
    Aliment Pharmacol Ther; 1999 Jan; 13(1):49-57. PubMed ID: 9892879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care--the CADET-HR Study.
    Armstrong D; Veldhuyzen van Zanten SJ; Barkun AN; Chiba N; Thomson AB; Smyth S; Sinclair P; Chakraborty B; White RJ;
    Aliment Pharmacol Ther; 2005 May; 21(10):1189-202. PubMed ID: 15882239
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
    Armstrong D; Paré P; Pericak D; Pyzyk M;
    Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of pantoprazole versus ranitidine in the treatment of patients with symptomatic gastroesophageal reflux disease.
    van Zyl J; van Rensburg C; Vieweg W; Fischer R
    Digestion; 2004; 70(1):61-9. PubMed ID: 15297779
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and costs of omeprazole vs ranitidine for treatment of symptomatic gastroesophageal reflux disease in primary care clinics in West Virginia.
    Kaplan-Machlis B; Spiegler GE; Zodet MW; Revicki DA
    Arch Fam Med; 2000 Jul; 9(7):624-30. PubMed ID: 10910310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators.
    Kahrilas PJ; Falk GW; Johnson DA; Schmitt C; Collins DW; Whipple J; D'Amico D; Hamelin B; Joelsson B
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1249-58. PubMed ID: 11012468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [25 years of gastric acid blockers].
    Lamers CB
    Ned Tijdschr Geneeskd; 1999 Dec; 143(50):2501-4. PubMed ID: 10627749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of omeprazole and histamine H2-receptor antagonists in the treatment of elderly and young patients with reflux oesophagitis.
    James OF; Parry-Billings KS
    Age Ageing; 1994 Mar; 23(2):121-6. PubMed ID: 8023719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Control of gastric acid with high dose H2-receptor antagonists after omeprazole failure: report of two cases.
    Leite LP; Just RJ; Castell DO; Lagerström PO
    Am J Gastroenterol; 1995 Oct; 90(10):1874-7. PubMed ID: 7572913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
    Festen HP; Schenk E; Tan G; Snel P; Nelis F
    Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis.
    Bate CM; Griffin SM; Keeling PW; Axon AT; Dronfield MW; Chapman RW; O'Donoghue D; Calam J; Crowe J; Mountfords RA; Watts DA; Taylor MD; Richardson PD
    Aliment Pharmacol Ther; 1996 Aug; 10(4):547-55. PubMed ID: 8853758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Health-related quality of life outcomes of omeprazole versus ranitidine in poorly responsive symptomatic gastroesophageal reflux disease.
    Revicki DA; Sorensen S; Maton PN; Orlando RC
    Dig Dis; 1998; 16(5):284-91. PubMed ID: 9892788
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials.
    Carlsson R; Galmiche JP; Dent J; Lundell L; Frison L
    Aliment Pharmacol Ther; 1997 Jun; 11(3):473-82. PubMed ID: 9218069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.